New funding from CEPI will help take a promising nanoparticle vaccine platform into early clinical development, with the aim of speeding up how we respond to future outbreaks.
More ⬇️
CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV).
Eligibility and how to apply: cepi.my.site.com/call-for-pro...
CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV).
Eligibility and how to apply: cepi.my.site.com/call-for-pro...
CEPI will award funding to advance scientifically robust, operationally feasible BDBV vaccine candidates that can move rapidly toward Phase 1 evaluation.
CEPI is especially seeking candidates with strong preclinical signals, rapid development timelines, and potential for scalable, equitable access. Developers, especially those in Africa or partnering with African institutions, are encouraged to apply via the CEPI Portal.
🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic.
More in the press release ⬇️
New funding will support the continued development of a pioneering vaccine platform.